Jose R Castillo-Mancilla1, Todd T Brown2, Kristine M Erlandson1, Frank J Palella3, Edward M Gardner1, Bernard J C Macatangay4, Elizabeth C Breen5, Lisa P Jacobson6, Peter L Anderson7, Nikolas I Wada6. 1. Division of Infectious Diseases, School of Medicine. 2. Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University School of Medicine. 3. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Division of Infectious Diseases/HIV/AIDS Unit, University of Pittsburgh School of Medicine, Pennsylvania. 5. Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA, University of California, Los Angeles. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 7. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-infected individuals exhibit residual inflammation regardless of virologic suppression. We evaluated whether suboptimal adherence to combination antiretroviral therapy (cART) is associated with greater residual inflammation than optimal adherence, despite virologic suppression. METHODS: Longitudinal self-reported cART adherence data and serum concentrations of 24 biomarkers of inflammation and immune activation were measured at the same study visit in HIV RNA-suppressed (<50 copies/mL) HIV-infected men in the Multicenter AIDS Cohort Study from 1998 to 2009. Associations between dichotomized 6-month (<100% vs 100%) and categorized 4-day (<85%, 85%-99%, and 100%) cART adherence with biomarker concentrations were evaluated. RESULTS: A total of 912 men provided 2816 person-visits with documented plasma HIV RNA suppression. In adjusted models, person-visits at which <100% cART 6-month adherence was reported had higher concentrations of interleukin 2, 6, and 10, interferon γ, tumor necrosis factor α, and C-reactive protein than person-visits at which 100% cART adherence (P < .05) was reported. These same differences were observed in person-visits reporting <85% versus 100% 4-day cART adherence, but not in visits reporting 85%-99% versus 100% cART adherence. After adjustment for multiple comparisons, tumor necrosis factor α remained significantly higher (11% increase; P < .001) in person-visits at which <100% adherence was reported. CONCLUSIONS: Higher concentrations of inflammatory biomarkers were observed among HIV RNA-suppressed men who reported <100% cART adherence than among more adherent men. Residual HIV replication (ie, below the limit of detection), more likely among men with suboptimal adherence, is a plausible mechanism. Whether improving cART adherence could affect residual inflammation and associated morbidity and mortality rates should be investigated.
BACKGROUND: Human immunodeficiency virus (HIV)-infected individuals exhibit residual inflammation regardless of virologic suppression. We evaluated whether suboptimal adherence to combination antiretroviral therapy (cART) is associated with greater residual inflammation than optimal adherence, despite virologic suppression. METHODS: Longitudinal self-reported cART adherence data and serum concentrations of 24 biomarkers of inflammation and immune activation were measured at the same study visit in HIV RNA-suppressed (<50 copies/mL) HIV-infectedmen in the Multicenter AIDS Cohort Study from 1998 to 2009. Associations between dichotomized 6-month (<100% vs 100%) and categorized 4-day (<85%, 85%-99%, and 100%) cART adherence with biomarker concentrations were evaluated. RESULTS: A total of 912 men provided 2816 person-visits with documented plasma HIV RNA suppression. In adjusted models, person-visits at which <100% cART 6-month adherence was reported had higher concentrations of interleukin 2, 6, and 10, interferon γ, tumor necrosis factor α, and C-reactive protein than person-visits at which 100% cART adherence (P < .05) was reported. These same differences were observed in person-visits reporting <85% versus 100% 4-day cART adherence, but not in visits reporting 85%-99% versus 100% cART adherence. After adjustment for multiple comparisons, tumor necrosis factor α remained significantly higher (11% increase; P < .001) in person-visits at which <100% adherence was reported. CONCLUSIONS: Higher concentrations of inflammatory biomarkers were observed among HIV RNA-suppressed men who reported <100% cART adherence than among more adherent men. Residual HIV replication (ie, below the limit of detection), more likely among men with suboptimal adherence, is a plausible mechanism. Whether improving cART adherence could affect residual inflammation and associated morbidity and mortality rates should be investigated.
Authors: Corrilynn O Hileman; Bruce Kinley; Valeska Scharen-Guivel; Kathy Melbourne; Javier Szwarcberg; Janet Robinson; Michael M Lederman; Grace A Mccomsey Journal: J Infect Dis Date: 2015-01-12 Impact factor: 5.226
Authors: Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt Journal: Adv Immunol Date: 2013 Impact factor: 3.543
Authors: Frank J Palella; Stephen J Gange; Lorie Benning; Lisa Jacobson; Robert C Kaplan; Alan L Landay; Russell P Tracy; Richard Elion Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Edmund A Bermudez; Nader Rifai; Julie Buring; JoAnn E Manson; Paul M Ridker Journal: Arterioscler Thromb Vasc Biol Date: 2002-10-01 Impact factor: 8.311
Authors: Christina Konstantopoulos; Heather Ribaudo; Kathleen Ragland; David R Bangsberg; Jonathan Z Li Journal: Open Forum Infect Dis Date: 2015-01-14 Impact factor: 3.835
Authors: Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.071
Authors: Jose R Castillo-Mancilla; Ryan P Coyle; Stacey S Coleman; Mary Morrow; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson Journal: AIDS Res Hum Retroviruses Date: 2019-07-30 Impact factor: 2.205
Authors: Kathy K Byrd; John G Hou; Ron Hazen; Heather Kirkham; Sumihiro Suzuki; Patrick G Clay; Tim Bush; Nasima M Camp; Paul J Weidle; Ambrose Delpino Journal: J Acquir Immune Defic Syndr Date: 2019-11-01 Impact factor: 3.731
Authors: Jessica E Haberer; Nicholas Musinguzi; Alexander C Tsai; Yap Boum; Bosco M Bwana; Conrad Muzoora; Peter W Hunt; Jeffrey N Martin; David R Bangsberg Journal: AIDS Date: 2017-01-02 Impact factor: 4.177
Authors: Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731
Authors: Mira Wang; Joshua D Miller; Shalean M Collins; Marianne V Santoso; Pauline Wekesa; Hideaki Okochi; Maricianah Onono; Sheri Weiser; Monica Gandhi; Sera L Young Journal: AIDS Behav Date: 2020-10